JP2012000112A5 - - Google Patents

Download PDF

Info

Publication number
JP2012000112A5
JP2012000112A5 JP2011166505A JP2011166505A JP2012000112A5 JP 2012000112 A5 JP2012000112 A5 JP 2012000112A5 JP 2011166505 A JP2011166505 A JP 2011166505A JP 2011166505 A JP2011166505 A JP 2011166505A JP 2012000112 A5 JP2012000112 A5 JP 2012000112A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
seq
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011166505A
Other languages
English (en)
Other versions
JP2012000112A (ja
Filing date
Publication date
Priority claimed from GBGB0410866.8A external-priority patent/GB0410866D0/en
Application filed filed Critical
Publication of JP2012000112A publication Critical patent/JP2012000112A/ja
Publication of JP2012000112A5 publication Critical patent/JP2012000112A5/ja
Pending legal-status Critical Current

Links

Claims (15)

  1. 配列番号3834の配列に対して少なくとも75%の配列同一性を有するアミノ酸配列を含む、ポリペプチド。
  2. 配列番号3834のアミノ酸配列を含む、請求項1に記載のポリペプチド。
  3. 配列番号3834の配列に由来する、少なくとも7個の連続するアミノ酸のフラグメントを含む、ポリペプチド。
  4. 前記フラグメントが、配列番号3834のアミノ酸配列に由来するT細胞エピトープもしくはB細胞エピトープを含む、請求項3に記載のポリペプチド。
  5. 請求項1〜4のいずれか1項に記載のポリペプチドに結合する、抗体。
  6. 前記抗体が、モノクローナル抗体である、請求項5に記載の抗体。
  7. 配列番号3833の配列に対して少なくとも75%の配列同一性を有するヌクレオチド配列を含む、核酸。
  8. 高ストリンジェンシー条件下で、配列番号3833の核酸にハイブリダイズ可能である、核酸。
  9. 配列番号3833に由来する10以上の連続するヌクレオチドのフラグメントを含む、核酸。
  10. 請求項1〜4のいずれか1項に記載のポリペプチドをコードする、核酸。
  11. (a)請求項1〜10のいずれか1項に記載のポリペプチド、抗体、および/または核酸と、
    (b)薬学的に受容可能なキャリアと
    を含む、組成物。
  12. さらにワクチンアジュバントを含む、請求項11に記載の組成物。
  13. 医薬として使用するための、請求項1〜11のいずれか1項に記載の核酸、ポリペプチド、または抗体。
  14. H.influenzaeによって引き起こされる疾患および/または感染を処置または予防するための医薬の製造における、請求項1〜11のいずれか1項に記載の核酸、ポリペプチドまたは抗体の使用。
  15. 中耳炎、気管支炎、結膜炎、静脈洞炎、尿路感染、肺炎、菌血症、化膿性関節炎、喉頭蓋炎、肺炎、蓄膿症、心膜炎、蜂巣炎、骨髄炎もしくは髄膜炎を予防するための、請求項1〜11のいずれか1項に記載の核酸、ポリペプチドまたは抗体、または、請求項14に記載の使用。
JP2011166505A 2004-05-14 2011-07-29 型分類不能なHaemophilusinfluenzae由来のポリペプチド Pending JP2012000112A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0410866.8 2004-05-14
GBGB0410866.8A GB0410866D0 (en) 2004-05-14 2004-05-14 Haemophilius influenzae

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007512595A Division JP2008506364A (ja) 2004-05-14 2005-05-16 型分類不能なHaemophilusinfluenzae由来のポリペプチド

Publications (2)

Publication Number Publication Date
JP2012000112A JP2012000112A (ja) 2012-01-05
JP2012000112A5 true JP2012000112A5 (ja) 2012-04-05

Family

ID=32527109

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007512595A Withdrawn JP2008506364A (ja) 2004-05-14 2005-05-16 型分類不能なHaemophilusinfluenzae由来のポリペプチド
JP2011166505A Pending JP2012000112A (ja) 2004-05-14 2011-07-29 型分類不能なHaemophilusinfluenzae由来のポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007512595A Withdrawn JP2008506364A (ja) 2004-05-14 2005-05-16 型分類不能なHaemophilusinfluenzae由来のポリペプチド

Country Status (10)

Country Link
US (4) US7749518B2 (ja)
EP (5) EP1745067A2 (ja)
JP (2) JP2008506364A (ja)
CN (1) CN1997663A (ja)
BR (1) BRPI0511118A (ja)
CA (1) CA2566632A1 (ja)
GB (1) GB0410866D0 (ja)
IN (1) IN2015KN00290A (ja)
RU (1) RU2432357C2 (ja)
WO (1) WO2005111066A2 (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1800385B (zh) * 2000-02-28 2010-06-02 启龙有限公司 奈瑟球菌蛋白质的异源表达
DK1549338T3 (da) * 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
US8283114B2 (en) * 2003-03-06 2012-10-09 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable Haemophilus influenzae
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
US20100034822A1 (en) * 2005-03-30 2010-02-11 Vega Masignani Haemophilus Influenzae Type B
ES2537274T3 (es) 2005-08-10 2015-06-05 Arne Forsgren Ab Interacción de Moraxella catarrhalis con células epiteliales, proteínas de la matriz extracelular y el sistema del complemento
NZ569417A (en) * 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2367568A2 (en) * 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
WO2010092176A2 (en) * 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
BR112013000392B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
CN103179984A (zh) 2010-08-31 2013-06-26 诺华有限公司 用于递送免疫原编码rna的peg化脂质体
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
MX2013013185A (es) * 2011-05-11 2014-06-05 Riesbeck Healthcare Sweden Ab Proteina f, una nueva adhesina de haemophilus influenzae con propiedades de unión a la laminina y vitronectina.
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
MX350764B (es) 2011-07-06 2017-09-18 Novartis Ag Liposomas con relacion nitrogeno:fosfato (n:p) util para el suministro de moleculas de arn.
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
EP2841096B1 (en) * 2012-04-26 2020-09-30 GlaxoSmithKline Biologicals SA Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
AU2014224205C1 (en) 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
US10502027B2 (en) * 2014-08-27 2019-12-10 Switchfloat Holdings Limited Oil field tubular and an internal sleeve for use therewith, and a method of deactivating a float valve within the oil field tubular
JP6731912B2 (ja) 2014-09-05 2020-07-29 ノバルティス アーゲー 活性物質の送達用の脂質および脂質組成物
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2016200787A2 (en) * 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯(北京)生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
US20180221468A1 (en) * 2017-01-19 2018-08-09 Iowa State University Research Foundation, Inc. Haemophilus influenzae immunogen
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3931206A1 (en) * 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccines targeting h. influenzae
EP4110906A4 (en) * 2020-02-28 2024-03-20 Trait Biosciences, Inc. NOVEL SYSTEMS, METHODS AND COMPOSITIONS FOR THE GLYCOSYLATION OF CANNABINOID COMPOUNDS
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
CN114574456B (zh) * 2022-03-18 2022-08-12 华南理工大学 一种亚硝酸盐还原酶突变体及其编码基因和应用
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
CN116236575A (zh) * 2023-03-07 2023-06-09 北京化工大学 一种光控偶联型纳米探针及其制备方法、光控偶联的纳米颗粒组合物与应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB234768A (en) * 1924-05-28 1925-08-27 Ritter Dental Mfg Company Inc Improvements in adjustable brackets for supporting head-rests or other articles
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002502882A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica e vacina que a compreende
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
KR20020038770A (ko) 1999-09-24 2002-05-23 장 스테판느 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US7262286B2 (en) 2000-09-26 2007-08-28 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2424275A1 (en) 2000-10-02 2002-04-11 Shire Biochem Inc. Haemophilus influenzae antigens and corresponding dna fragments
GB0026002D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
GB0109289D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Novel compounds
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0200025D0 (en) * 2002-01-02 2002-02-13 Glaxosmithkline Biolog Sa Novel compounds
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US8283114B2 (en) 2003-03-06 2012-10-09 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable Haemophilus influenzae
EP2330117A1 (en) * 2003-03-06 2011-06-08 Nationwide Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable Haemophilus influenzae
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
NZ569417A (en) 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
AT507024B1 (de) 2008-06-30 2011-10-15 Coil Holding Gmbh Drosselspule für elektrische energieversorgungsnetze mit reduzierten schallemissionen
WO2011106661A1 (en) 2010-02-25 2011-09-01 B/E Aerospace, Inc. Calibration method for led lighting systems

Similar Documents

Publication Publication Date Title
JP2012000112A5 (ja)
JP2008525033A5 (ja)
JP2008538183A5 (ja)
RU2006144093A (ru) Полипептиды нетипируемой haemophilus influenzae
JP2012126742A5 (ja)
JP2010166916A5 (ja)
JP2014051497A5 (ja)
JP2010273685A5 (ja)
RU2007139915A (ru) Haemophilus influenzae типа в
JP2012095652A5 (ja)
JP2011004753A5 (ja)
JP2013539454A5 (ja)
JP2017534262A5 (ja)
JP2011157378A5 (ja)
JP2012115277A5 (ja)
JP2012136541A5 (ja)
GB201206559D0 (en) Polypeptide
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2011528896A5 (ja)
JP2012522010A5 (ja)
JP2017507181A5 (ja)
JP2014074046A5 (ja)
RU2018132044A (ru) Антитела против тау
RU2013154779A (ru) Композиции для иммунизации против staphylococcus aureus
JP2010534684A5 (ja)